The Journal of the American Dental Association
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Am Dent Assoc, Vol 140, No 6, 658-669.
© 2009 American Dental Association

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Friedlander, A. H.
Right arrow Articles by Ettinger, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friedlander, A. H.
Right arrow Articles by Ettinger, R. L.

CLINICAL PRACTICE

JADA Continuing Education

Parkinson Disease

Systemic and Orofacial Manifestations, Medical and Dental Management



Arthur H. Friedlander, DMD, Michael Mahler, MD, Keith M. Norman, BA and Ronald L. Ettinger, BDS, MDS, DDSc, DABSCD

Background. More than 1.5 million Americans have Parkinson disease (PD), and this figure is expected to rise as the population ages. However, the dental literature offers little information about the illness.

Types of Studies Reviewed. The authors conducted a MEDLINE search using the key terms "Parkinson’s disease," "medical management" and "dentistry." They selected contemporaneous articles published in peer-reviewed journals and gave preference to articles reporting randomized controlled trials.

Results. PD is a progressive neurodegenerative disorder caused by loss of dopaminergic and nondopaminergic neurons in the brain. These deficits result in tremor, slowness of movement, rigidity, postural instability and autonomic and behavioral dysfunction. Treatment consists of administering medications that replace dopamine, stimulate dopamine receptors and modulate other neurotransmitter systems.

Clinical Implications. Oral health may decline because of tremors, muscle rigidity and cognitive deficits. The dentist should consult with the patient’s physician to establish the patient’s competence to provide informed consent and to determine the presence of comorbid illnesses. Scheduling short morning appointments that begin 90 minutes after administration of PD medication enhances the patient’s ability to cooperate with care. Inclination of the dental chair at 45o, placement of a bite prop, use of a rubber dam and high-volume oral evacuation enhance airway protection. To avoid adverse drug interactions with levodopa and entacapone, the dentist should limit administration of local anesthetic agents to three cartridges of 2 percent lidocaine with 1:100,000 epinephrine per half hour, and patients receiving selegiline should not be given agents containing epinephrine or levonordefrin. The dentist should instruct the patient and the caregiver in good oral hygiene techniques.

Key Words: Parkinson disease; local anesthetics; saliva

Abbreviations: MAOI: Monoamine oxidase inhibitor. • PD: Parkinson disease.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright©1995-2009 American Dental Association (ADA).
Reproduction or republication strictly prohibited without prior written permission of ADA.